Relay Therapeutics (NASDAQ:RLAY) Sets New 12-Month High – Time to Buy?

Relay Therapeutics, Inc. (NASDAQ:RLAY)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $9.19 and last traded at $8.6340, with a volume of 223483 shares. The stock had previously closed at $8.92.

Wall Street Analyst Weigh In

RLAY has been the topic of a number of recent analyst reports. Wells Fargo & Company raised Relay Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $6.00 to $13.00 in a research report on Friday, December 12th. Oppenheimer raised shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price target on the stock in a research note on Monday, January 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Relay Therapeutics Trading Down 4.0%

The firm has a market cap of $1.48 billion, a P/E ratio of -4.89 and a beta of 1.59. The firm has a 50-day simple moving average of $8.02 and a 200-day simple moving average of $6.18.

Relay Therapeutics (NASDAQ:RLAY) last posted its earnings results on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Research analysts predict that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Insider Transactions at Relay Therapeutics

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40. Following the completion of the sale, the chief financial officer directly owned 250,996 shares in the company, valued at approximately $1,912,589.52. The trade was a 5.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Peter Rahmer sold 11,684 shares of the company’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $89,032.08. Following the completion of the sale, the insider directly owned 277,964 shares in the company, valued at $2,118,085.68. This trade represents a 4.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 93,302 shares of company stock valued at $724,355 over the last three months. Company insiders own 4.87% of the company’s stock.

Institutional Trading of Relay Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its holdings in Relay Therapeutics by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock worth $956,000 after acquiring an additional 38,812 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Relay Therapeutics by 6.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock valued at $221,000 after purchasing an additional 5,238 shares during the period. Millennium Management LLC increased its stake in shares of Relay Therapeutics by 14.6% during the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after purchasing an additional 374,491 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Relay Therapeutics in the 1st quarter valued at about $53,000. Finally, Woodline Partners LP lifted its stake in Relay Therapeutics by 448.4% in the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock valued at $3,979,000 after buying an additional 1,241,657 shares in the last quarter. Institutional investors and hedge funds own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.